CR8167A - Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica - Google Patents

Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica

Info

Publication number
CR8167A
CR8167A CR8167A CR8167A CR8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A CR 8167 A CR8167 A CR 8167A
Authority
CR
Costa Rica
Prior art keywords
preparation
derivatives
substituted
espirobenzoacepine
peptidic
Prior art date
Application number
CR8167A
Other languages
English (en)
Inventor
Deng Xiaohu
Kenney Birdella
T Liang Jimmy
Mani Neelakandha
J Villani Frank
Zhang-Plasket Fan
Zhong Hua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8167A publication Critical patent/CR8167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos novedosos de espirobenzoazepina, procedimientos novedosos para la preparacion de derivados de espirobenzoazepina sustituidos que no son de peptido y procedimientos novedosos para la preparacion de intermediarios novedoso en la preparacion de dichos derivados; intermediarios novedoso en la preparacion de derivados espirobenzoazepina sustituidos que no son de peptidos.
CR8167A 2003-06-17 2006-01-02 Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica CR8167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47951503P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
CR8167A true CR8167A (es) 2008-09-10

Family

ID=33551892

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8167A CR8167A (es) 2003-06-17 2006-01-02 Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica

Country Status (20)

Country Link
US (2) US20040259857A1 (es)
EP (1) EP1633721A1 (es)
JP (1) JP2007516177A (es)
KR (1) KR20060023164A (es)
CN (1) CN1835926A (es)
AR (1) AR044781A1 (es)
AU (1) AU2004252135A1 (es)
BR (1) BRPI0411652A (es)
CA (1) CA2529513A1 (es)
CL (1) CL2004001508A1 (es)
CO (1) CO5650238A2 (es)
CR (1) CR8167A (es)
EA (1) EA200501829A1 (es)
HR (1) HRP20051005A2 (es)
IL (1) IL172629A0 (es)
IS (1) IS8185A (es)
NO (1) NO20060184L (es)
RS (1) RS20050933A (es)
TW (1) TW200510323A (es)
WO (1) WO2005000819A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086246B1 (ko) * 2003-06-17 2011-11-23 얀센 파마슈티카 엔.브이. 치환된 스피로벤즈아제핀
WO2007084591A2 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
DK2078022T3 (da) 2006-09-22 2012-02-13 Janssen Pharmaceutica Nv Spirobenzazepiner anvendt som vasopressinantagonister
US7825111B2 (en) 2006-09-22 2010-11-02 Janssen Pharmaceutica Nv Substituted spiroheterocycles
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
JP2009035513A (ja) * 2007-08-02 2009-02-19 Ube Ind Ltd ４−ｎ−（メチルベンゾイル）アミノ−２−メチル安息香酸の製法
CN105609662B (zh) * 2015-12-22 2017-12-12 洪杰波 一种钙钛矿光伏材料专用的空穴传输材料的制备方法
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
CN113735792B (zh) * 2021-09-22 2024-10-18 上海新礼泰药业有限公司 氯苯唑酸葡胺及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW462964B (en) * 1998-05-26 2001-11-11 Sumitomo Pharma Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same
MXPA03000135A (es) * 2000-07-05 2005-02-17 Johnson & Johnson Espirobenzoazepinas sustitudas no peptidicas como antagonistas de vasopresina.
KR101086246B1 (ko) * 2003-06-17 2011-11-23 얀센 파마슈티카 엔.브이. 치환된 스피로벤즈아제핀

Also Published As

Publication number Publication date
RS20050933A (sr) 2008-04-04
CL2004001508A1 (es) 2005-05-27
US20090105220A1 (en) 2009-04-23
EA200501829A1 (ru) 2006-06-30
HRP20051005A2 (en) 2006-09-30
KR20060023164A (ko) 2006-03-13
CO5650238A2 (es) 2006-06-30
AU2004252135A1 (en) 2005-01-06
WO2005000819A1 (en) 2005-01-06
EP1633721A1 (en) 2006-03-15
BRPI0411652A (pt) 2006-08-08
TW200510323A (en) 2005-03-16
AR044781A1 (es) 2005-10-05
IS8185A (is) 2005-12-15
IL172629A0 (en) 2006-04-10
US20040259857A1 (en) 2004-12-23
JP2007516177A (ja) 2007-06-21
CA2529513A1 (en) 2005-01-06
CN1835926A (zh) 2006-09-20
NO20060184L (no) 2006-03-13

Similar Documents

Publication Publication Date Title
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA200701918A1 (ru) Белок липокалин
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE335481T1 (de) Zolpidem hemitartrat solvat
ATE398630T1 (de) Zyklische conotoxin-peptide
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
UY27192A1 (es) Inhibidores de peptido-deformilasa
CR8167A (es) Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica
ITRM20020305A1 (it) Camptotecine con anello lattonico modificato.
BRPI0514672A (pt) polipeptìdeos de fusobacterium e métodos de uso
BR0316544A (pt) Compostos calcilìticos
DE60114567D1 (de) Selektive acylierung von a82846-glycopeptid-analoge
ITTO20030264A1 (it) Anello.
NO20044186L (no) Peptid-deformylaseinhibitorer
DE60220699D1 (de) Tibolonformulierungen
IT1338456B1 (it) Procedimento per la preparazione di alchiluree da o ,d-dimetil ditiocarbonato
ATE433953T1 (de) Peptiddeformylaseinhibitoren
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.
ITPN20020071A1 (it) Procedimento per la fabbricazione di mobili.
ES1053021Y (es) Disposicion mejorada para la ventilacion de naves.
ITTO20020465A0 (it) Procedimento per la preparazione di doxofillina.
ES1050413Y (es) Prensador para elaboracion de salazones y analogos.
ITTO20020290A0 (it) Anello
CY1115144T1 (el) Παραγωγα του uk-2a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)